Incretin-based drugs are potent weight-lowering agents, emerging as potential breakthrough therapy for the treatment of obesity-related phenotype of heart failure with preserved ejection fraction (HFpEF). In this review article, we will discuss the contribution of weight loss as part of the benefits of incretin-based medications in obese patients with HFpEF. Furthermore, we will describe the potential effects of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists on the heart, particularly in relation to HFpEF pathophysiology.

中文翻译：

---

超越减肥：基于肠促胰岛素的治疗在心脏代谢 HFpEF 中的新兴作用。

基于肠促胰岛素的药物是有效的减肥药，正在成为治疗肥胖相关表型射血分数保留的心力衰竭（HFpEF）的潜在突破性疗法。在这篇综述文章中，我们将讨论体重减轻的贡献，作为基于肠促胰岛素的药物对肥胖 HFpEF 患者的益处的一部分。此外，我们将描述胰高血糖素样肽 1 (GLP-1) 和葡萄糖依赖性促胰岛素多肽 (GIP) 受体激动剂对心脏的潜在影响，特别是与 HFpEF 病理生理学相关的潜在影响。